Fusion Antibodies (LSE:FAB), the Belfast-based antibody services specialist, continues to represent Northern Ireland's biotechnology sector among the constituents of the FTSE AIM All Share Index.
What the company does
Fusion Antibodies is a contract services organisation focused on therapeutic and diagnostic antibodies. It provides services to pharmaceutical and biotechnology customers across the drug discovery and early development process, including antibody discovery, sequencing, engineering and humanisation, and the supply of laboratory-grade material. Humanisation, which adapts antibodies so that they are better tolerated by the human immune system, has long been one of its core offerings. The company has also invested in platform technologies designed to improve antibody affinity and developability, and it has sought to apply computational and data-led methods to these processes. Its customers range from small biotechs to larger drug developers in Europe and North America.
Latest developments
Fusion Antibodies has a financial year ending on 31 March, so annual results are usually reported over the summer, with a half-year update to September following later. Historically, its newsflow has centred on contract wins, collaborations, platform developments and periodic trading statements.
Financial and dividend picture
As a services business, its income depends on the volume and size of customer projects, which in turn reflects biotech funding conditions. The company has not been known as a dividend payer, and smaller life sciences groups of this kind more commonly prioritise investment in capabilities and working capital than shareholder distributions.
Sector and index context
Fusion Antibodies (LSE:FAB) listed on AIM in 2017 and sits within the healthcare and life sciences grouping of the FTSE AIM All Share Index. Contract service providers are sensitive to the flow of venture capital and public funding into biotechnology. When financing is plentiful, early-stage developers tend to outsource more discovery work; when it tightens, programmes are delayed or cut, and orders can become lumpier. Antibody-based medicines remain one of the largest classes of new drugs, which supports long-term demand for specialist services, but competition from larger international contract service groups is significant.
Key risks
Key risks include dependence on a relatively concentrated customer base, the timing of orders, which can make results uneven, and exposure to a biotech funding cycle that the company does not control. Smaller AIM companies may also need to raise additional capital, which can dilute existing shareholders. Currency movements matter given its international customer base, and the shares may be thinly traded, which can lead to volatile price movements.
What to watch next
Investors are likely to focus on the company's next results or trading update, any new commercial agreements or repeat orders from larger customers, and progress in commercialising its technology platforms. Wider indicators, such as biotech financing activity and sentiment towards smaller healthcare shares, will also shape how Fusion Antibodies and its peers within the FTSE AIM All Share Index are viewed in the months ahead.






Please wait processing your request...